Serum FGF21 and RBP4 levels in patients with chronic hepatitis C

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 1037-1047

  Kukla, Michał ^a   Berdowska, Agnieszka ^b   Stygar, Dominika ^a   Gabriel, Andrzej ^a   Mazur, Włodzimierz ^a   Łogiewa Bazger, Beata ^a   Sobala Szczygieł, Barbara ^a   Bułdak, Rafał J ^a   Rokitka, Maria ^c   Zajecki, Wojciech ^a   Kepa, Lucjan ^a   Sawczyn, Tomasz ^a   Zwirska Korczala, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Chronic hepatitis C; Fibroblast growth factor 21; Insulin resistance; Liver; Retinol binding protein 4; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN 4;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE COUNT; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETINOL-BINDING PROTEINS, PLASMA; STATISTICS, NONPARAMETRIC;

EID: 84865706218     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.694901     Document Type: Article

References (40)

1. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Pupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54: 1003-8.
2. Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007;14: 600-7.
3. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis-pathogenic mechanism and clinical implications. Aliment Pharmacol Ther 2005;22(Suppl 2): 52-5.
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133: 592-9.
5. Perlemuter G, Sabile A, Letteron P, Strathdee SA, Szklo M, Thomas DL. Hepatitis C virus core protein inhibits micro-somal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related stea-tosis. FASEB J 2002;16: 185-95.
6. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenter-ology 2003;125: 1695-704.
7. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterol-ogy 2005;128: 636-41.
8. Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010;17: 661-7.
9. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58: 250-9.
10. Leandro G, Mangia A, Hui J, Fobris P, Rubia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
11. Bernsmeier Ch, Heima MH. Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance. Swiss Med Wkly 2009;139: 678-84.
12. Marra F, Bertolani C. Adipokines in liver diseases. Hepatol-ogy 2009;50: 957-69.
13. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010; 45: 235-42.
14. Chen W, Li L, Yang G, Li K, Qi XY, Zhu W, et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116: 65-8.
15. Zhang X, Yeung D, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57: 1246-53.
16. Chavez A, Molina-Carrion M, Abdul-Ghani M, Filli F, De Fronco RA, Tripathy D. Circulating fibroblast growth factor 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009;32: 1542-6.
17. Mraz M, Bartlova M, Lacinova Z, michalsky D, Kasalycky M, Halizikowa D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibro-blast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009;71: 369-75.
18. Kharitonenkov A, Shiyanova T, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115: 1627-35.
19. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Ataizi C, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40: 887-92.
20. Dushay J, Chui PC, Gopalakrishnan GS, Vraela-Rey M, Craweley M, Fisher MF, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010;139: 456-63.
21. Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez MM, Mateo MG, Fernandez I, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010;24: 2629-37.
22. van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007;53: 5-7.
23. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 1989;10: 308-16.
24. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm 2007;75: 1-32.
25. Petta S, Cammà C, Di Marco V, Allesi N, Barbaria F, Cabibi D, et al. Retinol binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology 2008;48: 28-37.
26. von Eynatten M, Lepper PM, Liu D, Lang K, Bauman M, Nawroth A, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007;50: 1930-7.
27. Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007;30: 1802-6.
28. Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, et al. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;79: 185-90.
29. Petta S, Tripodo C, Grimaudo S, Cabibi D, Camma C, Di Cristina A, et al. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic stea-tohepatitis. Digest Liver Dis 2011;43: 404-10.
30. Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007;30: 1168-72.
31. Bahr MJ, Boeker KH, Manns MP, Tietge UJ. Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Clin Endocrinol (Oxf) 2009;70: 60-5.
32. Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 2009;16: 716-23.
33. Huang JF, Dai CY, Yu ML, Shin SJ, Hsieh MY, Huang CF, et al. Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. J Hepatol 2009;50: 471-8.
34. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22: 112-14.
35. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Terti BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94: 2467-74.
36. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyc-eride. J Hepatol 2010;53: 934-40.
37. Kukla M, Gabriel A, Sabat D, Liszka L, Wilk M, Petelenz M, et al. Association between liver steatosis and angiogenesis in chronic hepatitis C. Pol J Pathol 2010;3: 154-60.
38. Palmentieri B, deSio I, LaMura V, Masarone M, Vecchione R, Torella R, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38: 485-9.
39. Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, et al. Retinol binding protein 4 expression in humans; relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007;92: 2590-7.
40. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. Diabetes Care 2007;30: 1173-8.